financetom
Business
financetom
/
Business
/
Kratos Defense Stock Is Trending Amid $274,000 Executive Stock Sale
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kratos Defense Stock Is Trending Amid $274,000 Executive Stock Sale
Sep 16, 2025 11:06 PM

Kratos Defense & Security Solutions Inc. shares are trending on Wednesday.

Check out the current price of KTOS stock here.

KTOS After-Hours Surge

KTOS increased by 0.34% in after-hours trading on Tuesday, reaching to $76.61.

The defense contractor has jumped 213.76% from its low of $24.39 in 2025, reaching $76.35 now. Trading volume has grown from 2.3 million to 5.3 million shares, which is significantly higher than the average volume of 3.39 million shares.

Executive Stock Sale Activity

Recent SEC Form 4 filings show that David M. Carter, President of the DRSS Division, sold 4,000 shares on September 12 through two transactions at average prices of $68.36 and $69.14 per share. These sales were part of a pre-scheduled trading plan set up on June 13, meaning they were planned in advance, not made based on market timing. The total amount from these transactions was $274,806.194.

See Also: SciSparc Stock Shoots Up Over 89% After Hours: What’s Going On?

Technical Fundamentals

The stock of the Californian company has experienced impressive growth over the past year, increasing by 244.70% from its 52-week low of $22.17, with a market capitalization of $12.89 billion.

KTOS is currently trading with a price-to-earnings ratio of 826.84 and is holding close to its 52-week high of $76.62.

Market Context

The after-hours gains suggest investor confidence remains intact despite insider selling activity.

Price Actiion: According to Benzinga Pro data shows KTOS closed at $76.35, gaining 7.93% during regular trading on Tuesday.

Benzinga's Edge Stock Rankings show Kratos Defense with strong performance across various categories: a Momentum score of 97.17, Growth at 89.77, and Quality at 77.18. The price trend is positive across short, medium, and long-term periods.  Know how its momentum lines up with other well-known names.

Read Next:

General Mills, Cracker Barrel And 3 Stocks To Watch Heading Into Wednesday

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Moderna Says Investigational Cancer Antigen Therapy Shows 'Promising' Early Data
Moderna Says Investigational Cancer Antigen Therapy Shows 'Promising' Early Data
Oct 13, 2025
08:30 AM EDT, 10/13/2025 (MT Newswires) -- Moderna ( MRNA ) said Monday that its investigational cancer antigen therapy, mRNA-4359, in combination with pembrolizumab, has shown promising results in its phase 1/2 trial in certain Melanoma patients. The company said the combination therapy achieved a 24% objective response rate and a 60% disease control rate. Among a subgroup of patients...
CleanCore Solutions Congratulates House of Doge on Successful Go-Public Transaction and Provides Treasury Update
CleanCore Solutions Congratulates House of Doge on Successful Go-Public Transaction and Provides Treasury Update
Oct 13, 2025
In collaboration with House of Doge and its strategic partners 21Shares and Robinhood, CleanCore will gain access to alpha-generating yield strategies designed to enhance treasury performance and long-term asset growth. House of Doge aims to accelerate Dogecoin’s adoption and real-world utility across commerce and paymentsHouse of Doge starts real-world tokenization initiatives, further accelerating the demand for dogecoin        ...
Bicara Therapeutics Says Potential Head, Neck Cancer Drug Gets FDA Breakthrough Therapy Designation
Bicara Therapeutics Says Potential Head, Neck Cancer Drug Gets FDA Breakthrough Therapy Designation
Oct 13, 2025
08:30 AM EDT, 10/13/2025 (MT Newswires) -- Bicara Therapeutics ( BCAX ) said Monday that ficerafusp alfa in combination with pembrolizumab for the treatment of head and neck squamous cell carcinoma, or HNSCC, has received Breakthrough Therapy Designation from the US Food and Drug Administration. The designation shows recognition of human papillomavirus-negative HNSCC as a clear clinical indication within head...
Blackboxstocks Inc. Announces its Merger Target REalloys inks LOI for a 10-Year Offtake Agreement for 15% of Tanbreez Production with Critical Metals Corp. to Strengthen North American Rare Earth Inde
Blackboxstocks Inc. Announces its Merger Target REalloys inks LOI for a 10-Year Offtake Agreement for 15% of Tanbreez Production with Critical Metals Corp. to Strengthen North American Rare Earth Inde
Oct 13, 2025
The LOI is for a 10-year off-take agreement, which plans to provide REalloys with long-term heavy rare earth feedstock from Critical Metals Corp.’s Tanbreez Project in Greenland, one of the world’s most significant deposits. REalloys’ strategic partnership aligns with U.S. and allied priorities to build a fully independent North American mine-to-magnet supply chain. NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE)...
Copyright 2023-2026 - www.financetom.com All Rights Reserved